Millennium Management LLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR) by 72.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,463 shares of the biotechnology company’s stock after selling 94,789 shares during the quarter. Millennium Management LLC owned 0.08% of United Therapeutics worth $3,971,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. IFM Investors Pty Ltd raised its stake in United Therapeutics by 12.2% during the fourth quarter. IFM Investors Pty Ltd now owns 2,644 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 288 shares in the last quarter. BB&T Corp raised its stake in United Therapeutics by 2.3% during the fourth quarter. BB&T Corp now owns 10,996 shares of the biotechnology company’s stock worth $1,197,000 after acquiring an additional 246 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in United Therapeutics by 5.1% during the third quarter. Thrivent Financial for Lutherans now owns 10,430 shares of the biotechnology company’s stock worth $1,334,000 after acquiring an additional 509 shares in the last quarter. First Citizens Bank & Trust Co. acquired a new position in United Therapeutics during the fourth quarter worth $217,000. Finally, First Trust Advisors LP raised its stake in United Therapeutics by 13.6% during the fourth quarter. First Trust Advisors LP now owns 1,196,804 shares of the biotechnology company’s stock worth $130,332,000 after acquiring an additional 143,235 shares in the last quarter. Institutional investors and hedge funds own 97.66% of the company’s stock.

Several research firms have issued reports on UTHR. Barclays dropped their price objective on United Therapeutics from $100.00 to $95.00 and set an “underweight” rating for the company in a research note on Friday, March 1st. BidaskClub upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. LADENBURG THALM/SH SH set a $124.00 price objective on United Therapeutics and gave the stock a “hold” rating in a research note on Thursday, February 28th. Cowen reiterated a “hold” rating and set a $109.00 price objective on shares of United Therapeutics in a research note on Wednesday, February 27th. Finally, Oppenheimer reiterated a “buy” rating on shares of United Therapeutics in a research note on Tuesday, March 19th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics currently has a consensus rating of “Hold” and an average target price of $133.11.

In related news, CEO Martine A. Rothblatt sold 14,108 shares of the firm’s stock in a transaction dated Monday, January 28th. The stock was sold at an average price of $115.37, for a total value of $1,627,639.96. Following the transaction, the chief executive officer now owns 7,194 shares in the company, valued at $829,971.78. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 7,054 shares of the firm’s stock in a transaction dated Tuesday, January 22nd. The shares were sold at an average price of $113.35, for a total value of $799,570.90. Following the completion of the transaction, the chief executive officer now owns 7,194 shares in the company, valued at approximately $815,439.90. The disclosure for this sale can be found here. Insiders have sold 46,094 shares of company stock worth $5,284,325 in the last 90 days. Company insiders own 8.20% of the company’s stock.

Shares of UTHR stock opened at $100.65 on Thursday. The company has a current ratio of 6.39, a quick ratio of 6.03 and a debt-to-equity ratio of 0.09. The firm has a market cap of $4.68 billion, a PE ratio of 7.52 and a beta of 1.10. United Therapeutics Co. has a 52 week low of $100.06 and a 52 week high of $130.00.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 27th. The biotechnology company reported $1.48 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.72). The business had revenue of $381.40 million for the quarter, compared to the consensus estimate of $355.81 million. United Therapeutics had a return on equity of 22.63% and a net margin of 36.20%. United Therapeutics’s revenue for the quarter was down 17.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.89 EPS. As a group, equities analysts predict that United Therapeutics Co. will post 9.28 EPS for the current year.

WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2019/04/18/millennium-management-llc-sells-94789-shares-of-united-therapeutics-co-uthr.html.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Read More: Put Option

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.